Thus, we could reasonably hypothesize that a larger study which did not select patients with HER2 amplifications and instead included all breast cancer patients would have concluded that approximately 4–20% of patients (compared to 15–80% of HER2-positive patients) would benefit from clinical use of trastuzumab. This evidence concerns the gene ERBB2 and breast carcinoma.